GT
KBIO

Glenmede Trust’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

Glenmede Trust’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-7,088
Closed -$13K – 2960
2015
Q3 		$13K Sell
7,088
-2
-0% -$5 ﹤0.01% 2049
2015
Q2 		$27K Hold
7,090
– – ﹤0.01% 1816
2015
Q1 		$27K Hold
7,090
– – ﹤0.01% 1861
2014
Q4 		$98K Buy
+7,090
New +$101K ﹤0.01% 1541

Other funds holding KBIO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $50.9B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return